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Supplemental Method
Supplemental Table Case UID17285 69 year-old male was diagnosed with stage IIIA Hodgkin's lymphoma. He was treated with 6 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy and achieved complete response. Approximately 2 years after the initial diagnosis of lymphoma, patient developed mild pancytopenia. Bone marrow biopsy revealed t-MDS with 3% blast. Cytogenetic analysis showed monosomal karyotype including monosomy 5 and 7. He was treated with decitabine for 3 cycles but developed pneumonia and subsequently died with respiratory failure.
Case UID19684 63 year-old male was diagnosed with stage III follicular lymphoma. There was no bone marrow involvement at initial diagnosis. He was treated with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for 6 cycles and achieved complete response. Approximately 3 years after initial diagnosis of follicular lymphoma, he developed mild cytopenia. Bone marrow biopsy revealed t-MDS with 8% blast and cytogenetic analysis showed monosomy 7. He was treated with lenalidomide and eltrombopag. After 5 months, his bone marrow showed increase in blast count and then he was treated with azacitidine and vorinostat for 3 cycles with stable disease. He then underwent cord blood stem cell transplant but he died at day 20 of transplant because of sepsis and multi-organ failure.
Case UID7394 74 year-old male was diagnosed with squamous cell carcinoma of penis. He was treated with cisplatin, ifosfamide and paclitaxel for 4 cycles followed by 65 Gy of radiation therapy. Approximately 3 years later, he was noted to have pancytopenia. Bone marrow biopsy revealed t-MDS with 3% blast and cytogenetic analysis showed complex abnormality. He was treated with azacitidine and vorinostat for 12 cycles and had hematological improvement. He then received single agent azacitidine for additional 4 cycles but lost response and progressed to AML. Subsequently, he developed respiratory failure and died approximately 1.5 years after the diagnosis of t-MDS.
Case UID49278 63 year-old male was diagnosed with stage I NSCLC. He was treated with concurrent chemo-radiation therapy with 66 Gy of radiation and weekly carboplatin and pemetrexed. Approximately 1 year after the initial diagnosis of NSCLC, he developed leukocytosis. Bone marrow biopsy revealed t-AML with 88% blast. Cytogenetic analysis showed -Y. He was treated with cladribine and low dose cytarabine and achieved complete remission after 1 cycle. He received total 9 cycles of this regimen and continues to maintain complete remission.
Case UID12484 64 year-old male was diagnosed with stage IV mantle cell lymphoma (MCL) and was treated with R-Hyper-CVAD chemotherapy (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine) for 5 cycles and achieved complete response. One year later, he had relapse and was treated with ibrutinib and rituximab. He again achieved complete response and received this therapy for 5 cycles. Approximately 2 years after the initial diagnosis of MCL, he developed pancytopenia. Bone marrow biopsy revealed t-AML with 28 % blast. Cytogenetic analysis revealed der (7;17)(p10;q10). He was treated with azacitidine and vorinostat for 3 cycles but with no response. He developed pneumonia and died approximately 4 months after the diagnosis of t-AML.
Case UID19304
25 year-old female was diagnosed with glioblastoma multiforme (GBM). She had tumor resection and received adjuvant chemotherapy with temozolamide for 12 months. Approximately 3 years from the initial diagnosis of GBM, she developed pancytopenia. Bone marrow biopsy revealed t-MDS with 13% blast and cytogenetic analysis showed inversion 3q. She was treated with fludarabine, idarubicin and cytarabine and achieved complete response after 1 cycle of therapy and received 1 cycle of consolidation therapy with the same chemotherapy. She then underwent matched unrelated donor stem cell transplant. At the time of this manuscript writing, she is day 84 of stem cell transplant and is doing well.
Case UID31000 40 year-old male was diagnosed with rhabdomyosarcoma in the right gluteus. He received neo-adjuvant chemotherapy consists of doxorubicin and ifosfamide for total 6 cycles and then received radiation therapy of 50 Gy in 25 fractions. He then underwent for radical resection of the mass. Approximately 2.5 years from the initial diagnosis of rhabdomyosarcoma, he developed pancytopenia. Bone marrow biopsy revealed t-AML with 31% myeloblast and cytogenetic analysis showed complex karyotype. He was treated with induction regimen consists of cladribine, idarubicin, and cytarabine and achieved complete remission. He received 1 cycle of consolidation therapy and underwent for matched unrelated donor stem cell transplant. He received 1 cycle of post-transplant azacitidine but at day 60, his bone marrow confirmed relapse of t-AML. He received salvage therapy with SGN-CD33a under clinical trial but with no response. He then received 1 cycle of decitabine but with no response. He developed pneumonia and died approximately 9 months after the diagnosis of t-AML. Of particular note, he was evaluated at familial cancer clinic when he was diagnosed with t-AML because his father and sister died from unknown cancer. He was confirmed to have Li-Fraumeni Syndrome because of the findings with 2 germline TP53 mutations.
Targeted gene sequencing of t-MN bone marrow samples and detection of high-confidence driver mutations
Genomic DNA was extracted from diagnostic BM aspirate samples using an Autopure extractor (QIAGEN/Gentra, Valencia, CA). DNAs were fragmented and bait-captured in solution as previously described according to manufacturer protocols.(1) Captured DNA libraries were then sequenced using a HiSeq 2000 sequencer (Illumina, San Diego, CA) with 76 basepair (bp) paired-end reads. Raw sequencing data from the Illumina platform were converted to a fastq format and aligned to the reference genome (hg19) using the Burroughs-Wheeler Aligner (BWA). (2) The aligned BAM files were subjected to mark duplication, re-alignment, and re-calibration using Picard and GATK (https://www.broadinstitute.org/gatk/guide/best-practices?bpm=DNAseq, last accessed 9/29/2016). Preprocessed BAM files were then analyzed to detect single nucleotide variants (SNV) and small insertions and deletions (indels) using MuTect(3) and Pindel(4) algorithms, respectively, against virtual normal sequence developed in-house. We modified an approach described by Pappaemanuil et al. to identify high-confidence driver mutations in the bone marrow samples without matched germline control.(5) First, variants with low quality supporting sequencing data were filtered out. Specifically, variants matching one or more of the following criteria were considered of low quality and therefore filtered out from further analysis: 1) tumor coverage < 15x and 20x for single nucleotide variants (SNVs) and insertions/deletions (indels), respectively, 2) tumor allele frequency < 5%, and 3) normal allele frequency >= 1% and 0% for SNVs and INDELs, respectively. Second, only variants which would introduce an obvious protein-coding change were kept for further analysis. Specifically, variant with an ANNOVAR annotation of non-synonymous, stop-gain, stop-loss, splicing, frameshift insertion, frameshift deletion, non-frameshift insertion or non-frameshift deletion was considered to be able to introduce an obvious protein-coding change and were therefore kept for further analysis. Third, common polymorphisms were removed to reduce the load of possible germline contamination due to the absence of matched normal. Specifically, a series of public variant database including the 1000 Genome Database (http://www.1000genomes.org/, last accessed 9/29/2016), ESP6500 Database (http://evs.gs.washington.edu/EVS/, last accessed 9/29/2016), dbSNP ver.132 (https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?build_id=132, last accessed 9/29/2016), and Exome Aggregation Consortium database (http://exac.broadinstitute.org/, last accessed 9/29/2016), were utilized. Variant with a population frequency of 0.14% or more in any of the databases was considered possible germline polymorphism and was therefore removed from further analysis. Finally, hierarchical classification system was developed to assign confidence level for each remaining variant in order to facilitate the identification of putative driver mutations. Specifically, each variant was classified based on the following hierarchical order and was assigned a confidence level corresponding to its rank in the system: 1) Confirmed somatic mutation based on COSMIC database (version 72), 2) loss-of-function mutation such as splicing, stop-gain, stop-loss and frameshift mutation in known tumor suppressor genes, 3) recurrent variant which resides within three amino acids away from a confirmed somatic mutation according to COSMIC database (version 72), 4) variant which resides within three amino acids away from a confirmed somatic mutation according to COSMIC database (version 72), 5) variant which was predicted to be damaging by in-silico function prediction algorithms, and 6) variant with unknown significance. The first three groups were considered high-confidence tier while the remaining were considered of low-confidence. The final annotated variant list was passed out of the pipeline and was further analyzed by manual inspection and literature mining in order to identify high-confidence driver mutations.
Molecular barcode sequencing using Haloplex High Sensitivity Assay
Illumina compatible libraries were prepared using Agilent's HaloPlex HS Target Enrichment System. Briefly, 50 ng of genomic DNA was fragmented using 16 restriction enzymes, in a double digestion format. The restriction fragments were pooled and hybridized to our custom biotinylated HaloPlex HS probe library. Molecular barcodes, Illumina index sequences and Illumina adapters were incorporated into the targeted fragments during hybridization. Nicks in the circularized probe-target hybridization products were then closed by DNA ligation. The circularized target-DNA-HaloPlex HS probe hybrids were captured on streptavidin beads and noncircular fragments were removed. The circular libraries were amplified by 24 cycles of PCR, purified using AMPure XP beads (Beckman Coulter), quantified fluorometrically using the Qubit™ dsDNA HS Assay (ThermoFisher). Enrichment was validated using the Agilent 2100 Bioanalyzer. The libraries were multiplexed 14 samples per pool and sequenced on the Illumina HiSeq4000 using the 150nt paired end format.
Rare variant calling and detection of clonal hematopoiesis
De-multiplexed sequence reads were first analyzed using the SureCall pipeline ver. 3.5 available from Agilent's website (http://www.genomics.agilent.com/en/NGS-Data-Analysis-Software/SureCall/?cid=AG-PT-154&tabId=AG-PR-1196, last accessed 9/29/2016). Briefly, reads were first trimmed and aligned to the human hg19 reference genome using BWA. Reads with the same molecular barcode sequence and mapped to the same genomic coordinates were considered to be derived from the same read family. For each read family, the consensus sequence was generated after removing random errors, which occurred in the minority of the reads within the read family. Read families with less than three unique reads were removed from further analysis. The aligned consensus reads were then subjected to variants calling using VarScan (http://varscan.sourceforge.net/, last accessed 9/29/2016). A binomial test was performed to calculate P-value for each variant by considering observed VAF and expected substitution rate at the given nucleotide position based on the entire sequenced population. After removing possible germline variants, the following filtering criteria were used: 1) alternative read count (Read2) ≥ 5, 2) binomial P-value < 1.0 x 10-6, 3) both strands called the variant, and 4) observed VAF is higher than the mean VAF for entire population at the given position. To be consistent with the prior definition of clonal hematopoiesis in healthy individuals, variants that passed the above filtering criteria were then annotated as clonal hematopoiesis if the variant matched with the list specified by Jaiswal et al. (6) Table S1. List of 295 genes targeted by next generation sequencing. ABCC9  CALR  CUL5  FANCD2  HIST1H2BF  LEF1  NBN  PLA2G2D  SF3B1  TINF2 (TIN2)   ABL1  CARD11  CUX1  FANCE  HIST1H3D  LRP1B  NCOR1  PLCG2  SFRS1  TLR2   ACTG1  CBL  CYLD  FANCG  HIST1H4D  LTB  NCOR2  POT1  SFRS7  TLR9   AKT1  CBLB  DAXX  FANCI  HNRNPK  LUC7L2  NF1  POU2AF1  SGK1  TNFAIP3   ANKRD11  CCND1  DCLRE1C  FANCL  HRAS  LYN  NFE2  PRDM1  SH2B3  TNFRSF14   ARID1A  CCND3  DDX3X  FAS  ICOS  MALT1  NFKB1  PRKCB  SHH  TNKS   ARID1B  CD200  DIS3  FAT1  ID3  MAP2K1  NFKB2  PTEN  SMAD2  TOX   ARID2  CD274  DKC1  FAT3  IDH1  MAPK1  NFKBIA  PTPN1  SMC1A BCL6  CHD2  EGR2  GATA1  IRF4  mIR15a  PALB2  RELB  STAG1  WHSC1   BCL7A  CHK2  ELANE  GATA2  IRF7  mIR16-1  PAX5  RELN  STAG2  WHSC1L1   BCOR  CIITA  EP300  GATA3  ITPKB  MIR17HG  PDCD1  RHOA  STAT1  WT1   BCR  CNOT3  EPHA7  GCET2  JAK1  mIR21  PDCD1LG2  RIPK1  STAT3  XPO1   BIRC3  CREBBP  EPOR  GFI1B  JAK2  mir34b  PDGFRB  ROBO1  SUZ12  ZAP70   BLK  CRLF2  ERG  GNA13  JAK3  mir34c  PEG3  ROR1  SYK  ZMYM2   BMI1  CSF2RA  ETV6  GNAS  JARID2  MLL  PHF6  RPL10  TBL1XR1  ZMYM3   BRAF  CSF3R  EZH2  GNB1  KDM4C  MLL2  PHIP  RPL5  TCF3  ZRSR2   BRIP1  CTBP1  FAM46C  GPRC5A  KDM6A  MLL3  PIGA  RUNX1  TERC   BTG1  CTBP2  FAM5C  HAX1  KIT  MPL  PIK3CA  RUNX2  TERT   BTK  CTCF  FANCA  HIST1H1E  KLHL6  MS4A1  PIK3CB  SAMHD1  TET1   BTLA  CTLA4  FANCB  HIST1H2AD  KRAS  MYB  PIK3CG  SETBP1  TET2   C22orf194  CTNNA1  FANCC  HIST1H2BE  LAMB4  MYD88  PIK3R1  SETD2  TGDS Table S2 . List of 32 genes targeted by Haloplex HS molecular barcode sequencing. Table S6 . Clinical characteristics of 5 patients in an independent cohort who developed t-MNs after therapy. Figure S1 .Summary of the changes of variant allele frequency (VAF) of all mutations from the time of primary cancer diagnosis to the time of t-MN diagnosis. Figure S2 . VAF difference of mutations in prior PB samples that became drivers and did not become drivers. Figure S5 .Comparison of the frequency of the mutated genes as clonal hematopoiesis between patients who developed t-MNs (N = 19) and patients who did not develop t-MNs (N = 123). One asterisk indicates P < 0.05 and two asterisks indicate P < 0.01.
Gene name
ASXL1 GATA2 KRAS SRSF2 ATM GNAS MYD88 STAG2 BCOR GNB1 NRAS STAT3 CBL IDH1 PHF6 TET2 CUX1 IDH2 PTPN11 TP53 DNMT3A JAK2 RAD21 U2AF1 EZH2 KDM6A RUNX1 WT1 FLT3 KIT SF3B1 ZRSR2of clinical characteristics of 14 patients who developed t-MNs (cases) and 54 patients with lymphoma who did not develop t-MNs after at least 5 years of follow up (control).
